|Bid||0.0000 x 1100|
|Ask||0.0000 x 1300|
|Day's Range||0.4163 - 0.4277|
|52 Week Range||0.3700 - 0.8500|
|Beta (5Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange, stating that it is not in compliance with certain continued listing standards as set forth in the NYSE American Company Guide. Based on the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2019, which was filed with the Securities and Exchange Commission (SEC) on November 4, 2019, the Company is below compliance with Part 10, Section 1003 of the NYSE American Company Guide since it reported stockholders' equity of $4.9 million and net losses in five of its most recent fiscal years as of September 30, 2019.
If you own shares in Synthetic Biologics, Inc. (NYSEMKT:SYN) then it's worth thinking about how it contributes to the...
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 25 cents. In the final minutes of trading on Wednesday, the company's shares hit 61 cents. A year ago, they were trading ...